Sign inJoin waitlistJoin the waitlist

PS

Paul Sabbatini

Senior Vice President for Clinical Research · New York Presbyterian Hospital

Credentials: · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
1992–1994
Internal Medicine
Vanderbilt University Medical Center
1989–1992
University of Mississippi School of Medicine
1985–1989

Research

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine · 2017 · 2,750 citations
OncoKB: A Precision Oncology Knowledge Base
JCO Precision Oncology · 2017 · 2,318 citations
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Journal of Clinical Oncology · 2016 · 2,075 citations

CA
Carol Aghajanian
75 papers
DS
David Spriggs
55 papers
MH
Martee Hensley
48 papers
JK
Jason Konner
27 papers
Dennis Chi
25 papers · 1 as a fellow
WT
William Tew
24 papers
RB
Richard Barakat
23 papers
Jakob Dupont
22 papers
RO
Roisin O'Cearbhaill
20 papers
NA
Nadeem Abu-Rustum
17 papers
Deborah Armstrong
10 papers
RG
Rachel Grisham
10 papers · 2 as a fellow

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $525.4K · Sloan-Kettering Inst Can Research
1997–2030
Immunologic Approaches to Ovarian Cancer
National Cancer Institute · P01
Contact PI · $7.4M · Sloan-Kettering Inst Can Research
2015–2021
Ovarian Cancer: Strategies for Consolidation
National Cancer Institute · K23
Contact PI · $629.1K · Sloan-Kettering Inst Can Research
2002–2008

Clinical trials

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2010–2017
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2010–2017
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Principal investigator · Completed · Phase 2
Gynecologic Oncology Group
2010
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal investigator · Completed · Phase 1
Ludwig Institute for Cancer Research
2008–2011